Literature DB >> 16985712

Determining the optimal treatment for advanced bladder cancer.

S J Freedland, D Chao, A J Pantuck, A Zisman, A S Belldegrun.   

Abstract

Entities:  

Year:  2001        PMID： 16985712      PMCID： PMC1476051     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  6 in total

1.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

Authors:  J P Stein; G Lieskovsky; R Cote; S Groshen; A C Feng; S Boyd; E Skinner; B Bochner; D Thangathurai; M Mikhail; D Raghavan; D G Skinner
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

2.  Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial.

Authors:  H von der Maase; L Andersen; L Crinò; S Weinknecht; L Dogliotti
Journal:  Ann Oncol       Date:  1999-12       Impact factor: 32.976

3.  Transurethral resection of muscle-invasive bladder cancer: 10-year outcome.

Authors:  H W Herr
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

4.  Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.

Authors:  D Kaufman; D Raghavan; M Carducci; E G Levine; B Murphy; J Aisner; T Kuzel; S Nicol; W Oh; W Stadler
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

5.  Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  M J Moore; E W Winquist; N Murray; I F Tannock; S Huan; K Bennett; W Walsh; L Seymour
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

6.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

Authors:  H von der Maase; S W Hansen; J T Roberts; L Dogliotti; T Oliver; M J Moore; I Bodrogi; P Albers; A Knuth; C M Lippert; P Kerbrat; P Sanchez Rovira; P Wersall; S P Cleall; D F Roychowdhury; I Tomlin; C M Visseren-Grul; P F Conte
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.